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Prediction of COPD-specific health-related quality of life in
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BACKGROUND: Health-related quality of life (HRQL) is an important patient-reported outcome for chronic obstructive pulmonary
disease (COPD).
AIM: We developed models predicting chronic respiratory questionnaire (CRQ) dyspnoea, fatigue, emotional function, mastery and
overall HRQL at 6 and 24 months using predictors easily available in primary care.
METHODS: We used the “least absolute shrinkage and selection operator” (lasso) method to build the models and assessed their
predictive performance. Results were displayed using nomograms.
RESULTS: For each domain-specific CRQ outcome, the corresponding score at baseline was the best predictor. Depending on the
domain, these predictions could be improved by adding one to six other predictors, such as the other domain-specific CRQ scores,
health status and depression score. To predict overall HRQL, fatigue and dyspnoea scores were the best predictors. Predicted and
observed values were on average the same, indicating good calibration. Explained variance ranged from 0.23 to 0.58, indicating
good discrimination.
CONCLUSIONS: To predict COPD-specific HRQL in primary care COPD patients, previous HRQL was the best predictor in our
models. Asking patients explicitly about dyspnoea, fatigue, depression and how they cope with COPD provides additional
important information about future HRQL whereas FEV1 or other commonly used predictors add little to the prediction of HRQL.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a systemic
disease with a great impact on patients’ lives.1,2 The majority of
COPD patients are treated in primary care and are usually seen by
their general practitioner at regular intervals. From a patient’s
perspective, one of the most important outcomes is health-related
quality of life (HRQL).3 To support management and shared
decision making on lifestyle changes and treatment in COPD
patients in primary care, it would be useful to predict (changes in)
their future course of HRQL based on current characteristics.
Prediction models can serve different purposes. For manage-
ment of COPD, one important purpose is to inform patients about
the future course of their disease and assist physicians and
patients with treatment decisions. In addition, these models can
support selection of the required patient spectrum for scientific
research on COPD4 and efficient subgroup analyses in randomised
trials.5 On average, prediction using formal prediction models has
been shown to be at least as accurate, more consistent and less
expensive than prediction by experienced clinicians.6
The majority of prediction models developed for COPD patients
predict mortality,7–18 although resource utilisation,19 health
status,20 hospitalisation7,16,19 and exacerbations7,21,22 have also
been used as outcomes. Although HRQL is arguably the most
relevant outcome from a patient’s perspective, so far the health-
activity-dyspnoea-obstruction (HADO) score seems to be the only
existing score that predicts HRQL.10 Specifically, the HADO index
was developed for classifying severity of COPD. It predicts HRQL,
as measured by several questionnaires (the SF-36 health survey,
the St George’s Respiratory Questionnaire and the chronic
respiratory questionnaire), and 3-year mortality using information
on dyspnoea, overall health and physical activity. The HADO score
was derived in men, discriminated only moderately between
patients with different levels of HRQL, as measured by the chronic
respiratory questionnaire (R2= 0.21) and it did not correct for
overoptimism.10
We describe here the development of prediction models for
domain-specific and overall HRQL in primary care COPD patients.
We have taken into account that deteriorations in, for example,
the dyspnoea domain may trigger consideration of different
therapeutic actions than similar deteriorations in, for example, the
emotional domain. We use nomograms to visualise the impact of
the different predictors on all outcomes: dyspnoea, fatigue,
emotional function, mastery and overall HRQL at 6 and 24 months.
MATERIALS AND METHODS
Study design and population characteristics
Our analyses were based on the international prospective cohort study
(International Collaborative Effort on Chronic Obstructive Lung Disease:
Exacerbation Risk Index Cohorts (ICE COLD ERIC)) with 409 primary care
COPD patients from Switzerland and the Netherlands. Details of the study
design and the baseline characteristics of the patients were published
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previously.23–26 Briefly, 409 COPD patients from primary care were
included in 2008/2009. 66%, 25% and 9% were in GOLD stages II, III and
IV, respectively; 41%, 21%, 15% and 23% in GOLD stages A–D, respectively.
The study is ongoing and will be completed in 2014 after 5 years of follow-
up. Patients are followed biannually through telephone interviews and live
visits at baseline and after 2 and 4 years of follow-up. The analyses
reported here are based on the 2-year follow-up data. The study has been
approved by all local medical ethics committees (Academic Medical
Center, University of Amsterdam, The Netherlands; Kanton of Zurich,
Switzerland and Kanton of St Gallen, Switzerland) and all patients provided
written informed consent.
Outcome
The outcome was COPD-specific HRQL at 6 and 24 months as measured by
the self-administered chronic respiratory questionnaire (CRQ).27,28 The CRQ
consists of 20 questions providing a total score and four domain-specific
summary scores for dyspnoea, fatigue, emotional function and mastery,
all on 7-point scales, where 1 indicates the worst and 7 the best
possible score.
Candidate predictors
We used the data collected at baseline to develop the prediction models.
All candidate predictors were specifically selected on the basis of their
likely predictiveness and practicality in primary care. Details of the
candidate predictors and the data at baseline were published
previously.23,24 Table 1 summarises all candidate predictors.
Nomograms
We simplified the potential application of the prediction models by
creating nomograms. For reasons of readability and practicality, some
Table 1. Candidate predictors and their characteristics
Candidate predictors Coding p5, p50, p95 No. of missings out of 409 (%)
Sexa 1=male, 2= female 57 0 (0)
Age Continuous (years) 52, 67, 83 0 (0)
Body mass index Continuous (kg/m2) 19, 25, 35 0 (0)
Living situationa 1= single, 2=partner/children 36 2 (0.5)
Smoking statusb 1= smoker, 2= former smoker, 3=never smoker 41, 54, 5 1 (0.2)
Cougha 0=no, 1= yes 49 0 (0)
Phlegma 0=no, 1= yes 48 3 (0.7)
Exacerbations
At home Count 0, 0, 1 0 (0)
In hospital Count 0, 0, 0 0 (0)
Medicationa
Anxiolytics 0=no, 1= yes 14 0 (0)
Antidepressants 0=no, 1= yes 11 0 (0)
Cardiovascular 0=no, 1= yes 65 0 (0)
Pulmonary 0=no, 1= yes 82 0 (0)
Long-acting beta-agonistsb 0=no, 1= yes 59 0 (0)
Inhaled corticosteroidsb 0=no, 1= yes 60 0 (0)
Vaccinationa
Influenza 0=no, 1= yes 78 1 (0.2)
Pneumococcal 0=no, 1= yes 7 1 (0.2)
Physical activitya 0=no, 1= yes 24 0 (0)
Comorbidity:a
Cardiovascular 0=no, 1= yes 20 0 (0)
Neurological 0=no, 1= yes 9 0 (0)
Renal 0=no, 1= yes 19 0 (0)
Diabetes mellitus 0=no, 1= yes 15 0 (0)
Musculoskeletal 0=no, 1= yes 29 0 (0)
Psychiatric 0=no, 1= yes 19 0 (0)
Lung function (FEV1% of predicted) Continuous (%) 25, 59, 78 0 (0)
Feeling thermometer Continuous (0–100) 45, 70, 95 1 (0.2)
HRQL: 4 CRQ domains Continuous (1–7)
Dyspnoea 2.2, 4.8, 7.0 0 (0)
Fatigue 2.0, 4.5, 6.5 0 (0)
Emotional function 2.7, 5.4, 6.7 0 (0)
Mastery 3.3, 5.8, 7.0 0 (0)
Depression score (HADS) Continuous (0–21) 1, 5, 11 0 (0)
Physical activity score (LAPAQ) Continuous (0–7) 1, 4, 6 0 (0)
Self-efficacy, 3 questions Continuous (1–5)
SEI 1 (illness-related) 2, 4, 5 1 (0.2)
SEI 2 (dyspnoea-related) 1, 4, 5 2 (0.5)
SEI 3 (medication-related) 1, 5, 5 30 (7.3)
Handgrip test, best of 6 attempts Continuous (kg) 18, 34, 56 0 (0)
Sit to stand test Count (repetitions/min) 0, 17, 37 0 (0)
Abbreviations: CRQ, chronic respiratory questionnaire; FEV1, forced expiratory volume in 1 s, HADS, Hospital Anxiety and Depression Scale; HRQL, health-
related quality of life; LAPAQ, LASA (Longitudinal Ageing Study Amsterdam) Physical Activity Questionnaire; p5, 5th centile; p50, median; p95, 95th centile.
aFor binary variables, the number in the third column is the percentage of patients with code 1, for example, 57% is male and 49% has a cough.
bFor this categorical variable, the numbers in the third column are the percentages of patients with code 1, 2 and 3, respectively, for example, 41% is a smoker.
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predictors that were initially retained by the lasso procedure (see below)
were dropped from the nomograms as they turned out to be weak
predictors. We defined ‘weak’ as an effect of o5 on the upper points scale
(see nomogram in Figure 3), which corresponds to a change of o0.1 on
the HRQL outcome scale, clearly less than the minimal important
difference of 0.5.29
Missing data
Missing data were multiply imputed (10 times) via chained equations (mice
package in R version 2.15.2).30 Only patients who were alive at 6 or
24 months were considered.
Statistical analysis
Predictor selection and model fitting were based on penalised linear
regression using the “least absolute shrinkage and selection operator”
(lasso).31,32 The lasso allows for automatic variable selection on the basis of
predictive value (see Supplementary Appendix for details). In summary, the
lasso performs backward selection of variables in combination with a
penalty on the absolute value of the regression coefficients, such that
some are set to zero whereas others are shrunk towards smaller (absolute)
values. Compared with standard backward selection, the additional
shrinkage improves model performance in new patients.
Calibration of the final model was assessed by comparing the means of
predicted values against the means of observed outcomes by deciles of
predicted values. Model discrimination was expressed as explained
variance (EV). EV expresses increase in predictive performance relative to
a model that does not include any predictor. For the measure of predictive
value that we used, EV is the same as R2. Often, prediction models perform
well in the data set in which they have been developed. But when applied
to new patients or other populations, predictive performance may be less.
It is possible to (partly) correct for this so-called overoptimism. Although
the lasso is expected to show less overoptimism than backward
elimination, we still corrected for overoptimism in calibration and
discrimination performance using bootstrap resampling.33 No confidence
intervals are given, because there are currently no validated methods to
calculate them when bootstrap-based correction for overoptimism is used.
Analyses were done using Stata (version 10.1), the R statistical computing
environment (version 2.15.2) and the caret and glmnet packages in R. See
Supplementary Appendix for more elaborate statistical information.
RESULTS
Table 2 shows selected predictors and their regression coefficients
for all prediction models. For all CRQ outcomes, the best predictor
was that particular CRQ score at baseline (regression coefficients
0.66, 0.63, 0.56 and 0.43 for dyspnoea, fatigue, emotional function
and mastery, respectively). For each CRQ outcome some
additional predictors were selected, such as the feeling thermo-
meter for dyspnoea and the HADS depression score for fatigue.
See Supplementary Appendix Table 1 for all regressions equations.
Discrimination performance of the models
Figure 1 shows the EVs for all outcomes (four domains and overall
HRQL) for 6 and 24 months. EV scores ranged from 0.23 to 0.58
and were higher for 6-months than for 24-months prediction. The
mastery domain had the lowest values. See Supplementary
Appendix Table 2 for all EVs.
Calibration performance of the models
Figure 2 visually displays calibration for the dyspnoea outcome.
The other models were similar (see Supplementary Appendix
Figures 1 and 2). For at least 90% of the deciles, the predicted CRQ
values did not differ from those observed by 40.5, the minimal
important difference.29 Note that CRQ dyspnoea scores were
relatively high, which is to be expected in this primary care cohort.
Nomograms
Figure 3 shows the nomogram to predict dyspnoea at 6 months.
Figure 4 illustrates how the nomogram should be used and read
off. See Supplementary Appendix Figure 3 for the nomograms for
the other outcomes. All predictors can be read from these
nomograms, as well as their contribution to the prediction.
DISCUSSION
Main findings
We found that COPD-specific HRQL after 6 and 24 months in
primary care COPD patients could be reasonably well predicted by
the corresponding domain-specific score at baseline. As expected,
six-months predictions turned out to be better than 24-months
predictions and dyspnoea, fatigue and emotional function were
easier to predict than mastery. These models could be improved
by adding between one to six other predictors to the strongest
Table 2. Selected predictors and their regression coefficients
Selected predictors Scale 6 Months 24 Months
CRQ dyspnoea
CRQ dyspnoea 1–7 0.6644 0.6559
CRQ fatigue 1–7 0.0759
Lung function (FEV1% of
predicted)
Continuous 0.0046
Feeling thermometer 0–100 0.0042 0.0008
Pulmonary medication Dichotomous − 0.0115
CRQ fatigue
CRQ fatigue 1–7 0.6299 0.5212
HADS depression score 0–21 − 0.0270 − 0.0241
CRQ emotional 1–7 0.0115
CRQ dyspnoea 1–7 0.0039 0.1057
Feeling thermometer 0–100 0.0008
Country Dichotomous 0.0472
CRQ emotional function
CRQ emotional function 1–7 0.5593 0.6105
HADS depression score 0–21 − 0.0569 − 0.0136
CRQ dyspnoea 1–7 0.0498
CRQ fatigue 1–7 0.0439 0.0049
Self-efficacy 2a 1–5 0.0098
CRQ mastery
CRQ mastery 1–7 0.4284 0.3692
CRQ fatigue 1–7 0.0939 0.0156
CRQ dyspnoea 1–7 0.0605 0.0545
HADS depression score 0–21 − 0.0165 − 0.0082
Self-efficacy 2a 1–5 0.0350
CRQ emotional 1–7 0.1045
CRQ total score
CRQ fatigue 1–7 0.2444 0.1664
CRQ dyspnoea 1–7 0.2397 0.2553
HADS depression score 0–21 − 0.0364 −0.0221
CRQ mastery 1–7 0.0264
Self-efficacy 2a 1–5 0.0388




Abbreviations: CRQ, chronic respiratory questionnaire; FEV1, forced
expiratory volume in 1 s; HADS, Hospital Anxiety and Depression Scale,
LAPAQ, LASA (Longitudinal Ageing Study Amsterdam) Physical Activity
Questionnaire.
aSelf-efficacy 2 pertained to the following question: ’How confident were
you during the past 2 weeks that you were in control of your
breathlessness, so the breathlessness did not hold you back from the
things you wanted to do?’.
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predictor, such as the HADS, the feeling thermometer and the
other domain-specific CRQ scores. The predictions were close to
the average observed values and within limits demarcated by the
minimal important difference of 0.5.29 This indicates good
calibration. Explained variances (EV) were high and 40.4 with
the exception of mastery whereas the HADO score from an earlier
published model had an EV of 0.21.
Candidate predictors
All candidate predictors were selected on the basis of their likely
predictiveness of HRQL and their practicality in primary care
settings. According to Tsiligianni et al.,34 HRQL is strongly
associated with dyspnoea, depression, anxiety and exercise
tolerance, all of which were candidate predictors in our study.
Some potentially important but more difficult to collect predictors
may have been omitted, such as the 6-minute-walk test to
measure exercise capacity. We decided to use the more practical
1-minute sit-to-stand and handgrip strength tests, which are
strongly associated with HRQL. With regard to assessing self-
efficacy, we used three questions, which were not formally
validated.
There were few missing data. In particular, only 19 out of 409
patients were lost to follow-up (4.6%) at 24 months. With regard to
predictors, across eight candidate predictors o1% of values were
missing and for one candidate predictor 7% of values were
missing (see Table 1). All other data were complete. Multiple
imputation was used for missing values.
Strengths and limitations of this study
Our study has some limitations. First, as with all prediction models
based on current practice data, major changes in treatment
practice may decrease predictive value of the models. For
example, if some new and effective intervention will be developed
and extensively used in COPD care, our models could lose some
predictive value. Second, we only modelled main effects, no
interactions. We cannot exclude that particular combinations of
two or more candidate predictors have additional predictive value
over and above that provided by the individual candidate
predictors. Third, although we corrected for overoptimism, the
models were only validated internally, that is, within the same
data set. Therefore, the models may benefit from formal validation
on data from other patients (external validation).
We see the following strengths of our study. First, HRQL is one
of the most important outcomes from a patient’s perspective and
the primary outcome measure of the ICE COLD ERIC cohort. The
CRQ, which is a validated questionnaire,27,28 enabled us to exploit
its four domains and develop domain-specific models to assist
(shared) decision making directed at clinically clearly demarcated
outcomes. Another practical advantage of the CRQ is that it is a
patient-reported outcome. Second, in both countries the patients
were recruited from primary care and all candidate predictors
were explicitly selected on the basis of their practicality in primary
care settings. Third, all questionnaires were validated except for
the self-efficacy questions. Fourth, for each country an adjudica-
tion committee of experienced general practitioners and pulmo-
nologists assessed the exacerbations. Fifth, practical nomograms
were developed facilitating the use of the models in everyday
care. Finally, the use of advanced statistical methods enabled us to
correct for overoptimism and increase the external validity of our
models. The lasso method also reduced the size of the models
keeping them as practical as possible in busy practice.
Interpretation of findings in relation to previously published work
So far, only the HADO score has been developed to predict HRQL
in COPD patients. Unfortunately, the HADO score was derived in
men, and it showed moderate discrimination (R2= 0.21) for
HRQL10 and was not corrected for overoptimism.
Implications for future research, policy and practice
In COPD research, many prediction models predicting death (or
age at death) exist.7–18 There are a few models that predict the
probability of new exacerbations as a function of patient
characteristics.7,21,22 These models have in common that age
and the number of exacerbations in the previous year are among
the strongest predictors of the two phenomena that these models
predict, respectively. From a patient’s perspective, one of the most
important outcomes is (disease-specific) HRQL.3 The burden of
Figure 2. Calibration curve for the dyspnoea model at 6 months.
x axis, predicted CRQ score; y axis, observed CRQ score (scores range
from 1 (worst) to 7 (best)); (──) diagonal, x= y, perfect prediction;
(- - -) regression line, note that predicted score 4 observed score up
to a predicted score of 4.5, and predicted score o observed score
for values above 4.5; (······)± 0.5 (minimal important difference); (■)
deciles, note that all deciles remained within the 0.5 range, meaning
that the average per decile is within the limits of the minimal
important difference; grey numbers, all predicted values per decile.
Note that CRQ dyspnoea scores are relatively high, which is
expected in this primary care cohort.
Figure 1. Explained variance (EV) of the prediction models at 6 and
24 months for mastery, emotional function, fatigue, dyspnoea and
overall health-related quality of life.
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COPD differs between patient groups; some are almost untouched
by the disease whereas others can be completely handicapped.
These differences can be captured by health-related quality of life,
namely, that part of quality of life (ability to enjoy normal life
activities) that is determined by health. HRQL includes several
dimensions such as general health status (an overall evaluation of
a person’s health), mental and psychological status, the ability to
perform social activities and so on. COPD-specific HRQL is the
potential impact of COPD on the HRQL. The GOLD guidelines
recommend using repeated measurements on COPD-specific
HRQL questionnaires for monitoring and follow-up. Still, perform-
ing repeated measurements only will not improve a patient’s
HRQL. A major goal in the management of patients with COPD is
to ensure that the burden of the disease is as limited as possible
and the COPD-specific HRQL is as good as possible.3,34
Our current study shows that COPD-specific HRQL is no
exception to the rule that a previous measurement of a
phenomenon usually is a strong predictor of the (probability of)
the next occurrence. A prediction model as such only does what
the name suggests: predict. By itself, it does not change the course
of disease. The latter, arguably the most important aim, comes
about by acting on the prediction appropriately. Evidence external
to the prediction model studies is needed to learn which actions
may change the disease course or the probabilities of any
untoward events predicted.
In daily clinical practice, our models can be used to inform
patients about future HRQL. Since all predictors are available in
primary care, general practitioners can use the models to predict
their patients’ courses in different domains of, and in overall,
HRQL. All predictors in the models are medically plausible in their
capacity to predict HRQL. A commonly used predictor, such as
FEV1, does not seem to be a strong predictor of HRQL. Depending
on the outcome per domain, general practitioners and patients
can discuss and try to prioritise different treatment actions.
Figure 3. Nomogram for CRQ dyspnoea outcome at 6 months. FEV1, forced expiratory volume in 1 s; FT, feeling thermometer; CRQ, chronic
respiratory questionnaire.
Figure 4. Example of using the nomogram. FEV1, forced expiratory volume in 1 s; FT, feeling thermometer; CRQ, chronic respiratory
questionnaire. From each predictor scale, draw a vertical line up through the points scale (upper scale) and sum all points, Next, fill in the sum
value in the total points scale, draw a vertical line through the outcome variable (here dyspnoea at 6 months) and read off the predicted
outcome.
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Suppose our models predict that, in the next 6 months, a patient
will clearly decline in the dyspnoea domain. It is known that
pulmonary rehabilitation has a beneficial effect on all domains of
HRQL and on dyspnoea in particular.35,36 According to Lacasse
et al.,37 on average, pulmonary rehabilitation improves the CRQ
dyspnoea score by more than 1 point, clearly exceeding the
minimal important difference of 0.5. Our models can be used in
daily clinical practice to show patients their expected course on
(different domains of their) HRQL and, in the case of marked
decline in one or more domains, they may assist the physician and
patient to prioritise treatment decisions. In our example patient,
one may discuss with the patient the option of a pulmonary
rehabilitation programme to prevent the expected decline in the
dyspnoea domain.
Suppose that an effective intervention is very cheap and has no
adverse events. Obviously, no prediction model is needed as all
patients may receive this intervention. However, this is rare.
Usually, effective interventions are (somewhat) costly and do have
adverse events. In this case, a high predicted risk is usually needed
to justify the use of that intervention. Prediction models may help
clinicians in the decision making process.
Future studies should further validate our models in other
populations with respect to discrimination and calibration. Also,
data from randomised trials and meta-analyses can be incorpo-
rated or linked to our models to estimate how the prediction of
HRQL is likely to change when adding treatments such as smoking
cessation programs, pulmonary rehabilitation or specific drug
treatments.38,39 Finally, cost-effectiveness evaluation of prediction
models for HRQL in COPD should be performed to determine if it
is worth the effort incorporating these models into practice. After
successful completion of these steps, our models can support
treatment selection on the basis of the individual patient’s
prognosis.
Conclusions
To predict COPD-specific HRQL in primary care COPD patients,
previous HRQL is the best predictor. Asking patients explicitly
about dyspnoea, fatigue, depression and coping with COPD
provides additional important information about future HRQL
whereas FEV1 and some other commonly used predictors, such as
exercise capacity add little to the prediction of HRQL.
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